Consumer groups urge Congress not to rush FDA rulemaking on CBD

A few health and consumer advocacy organizations are urging Congress “to reject any attempts to force federal regulators” to legalize CBD immediately.

In a June 17 letter to Congress members, the organizations say Congress itself “is not the right evaluator of the safety of consumer products” because representatives and senators can be influenced by “well-funded profiteers” who want their products to bypass oversight.

The letter was signed by leaders from Consumer Reports, Public Health Institute, Consumer Federation of America, and the Center for Science in the Public Interest.

Hemp Today first reported details of the letter.

The hemp and CBD industry have been waiting for years for regulatory guidance from the U.S. Food and Drug Administration and have expressed frustration about the long process.

The letter says Congress should ensure the FDA is not “rushed to make a judgement about CBD that may impact the health and safety of millions of consumers.” Further, the letter states that now is not the time for the FDA to come to any conclusions about CBD because the agency is focused on dealing with a pandemic.

 

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *